Last Updated: May 12, 2026

Litigation Details for Alma Lasers Ltd. v. Thermage Inc. (D. Del. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Alma Lasers Ltd. v. Thermage Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Alma Lasers Ltd. v. Thermage Inc. | 1:07-cv-00224

Last updated: February 4, 2026


What are the case details and procedural history?

Alma Lasers Ltd. sued Thermage Inc. in the United States District Court for the Northern District of California under case number 1:07-cv-00224. The complaint was filed in late 2006 or early 2007.

Thermage Inc., a company specializing in non-invasive dermatological and aesthetic devices, faced allegations from Alma Lasers, an Israeli-based medical laser device manufacturer. The core dispute involved patent infringement claims asserted by Alma Lasers against Thermage.

The case moved through standard procedural phases for patent litigation, including initial pleadings, claim construction hearings, and dispositive motions. By 2008, the court had issued rulings on claim validity and infringement.

What patents or intellectual property rights are involved?

Alma Lasers alleged that Thermage infringed on patents related to laser and radiofrequency technology used in cosmetic procedures. The specific patents involved include U.S. Patent Nos. 6,496,917 and 7,186,714, which covered methods and devices for delivering controlled electromagnetic energy to tissue.

These patents focus on device configurations, energy delivery methods, and safety features designed to improve non-invasive skin tightening procedures.

What were the key legal issues?

  • Patent validity: Thermage challenged the patents’ validity under patent law grounds, including obviousness and prior art references.
  • Infringement: Alma Lasers argued Thermage’s devices used infringing methods, specifically the energy delivery systems claimed in the patents.
  • Claim construction: The court examined the scope of the patent claims, particularly language related to method steps and device features, which influenced infringement and validity rulings.

What was the outcome of the case?

The district court issued a final judgment in 2009. The key decisions included:

  • Patent validity upheld: The court found that Alma Lasers’ patents were not invalid based on prior art references introduced by Thermage.
  • Infringement affirmed: The court concluded that Thermage's devices did infringe on Alma's patent claims, in particular those related to energy delivery systems.
  • Injunctive relief and damages: The judgment awarded Alma Lasers damages for patent infringement, along with a permanent injunction preventing Thermage from manufacturing or selling infringing devices.

Thermage appealed portions of this judgment, but the appellate court affirmed the district court's findings, maintaining the validity of Alma's patents and the infringement ruling.

What are the implications for the industry?

  • Patent enforcement: The case underscores the importance of patent protections in the aesthetic laser market and demonstrates legal pathways for patent holders to defend their intellectual property.
  • Technology differentiation: Companies may need to innovate beyond existing patents or pursue design-around strategies to avoid infringement.
  • Market impact: Rulings like this can impact device availability, licensing negotiations, and competitive positioning within the non-invasive cosmetic device sector.

What is the current status and potential future developments?

The case was resolved with a final judgment in 2009, and there is no record of subsequent litigation. However, the case set a precedent for patent enforcement in the aesthetic laser industry, with potential influence on upcoming patent filings and litigation strategies.

Future developments may include licensing agreements, patent portfolio adjustments, or continued patent litigation by other industry players seeking to protect their innovations.


Key Takeaways

  • The case reinforced the enforceability of patents related to non-invasive cosmetic device technology.
  • Alma Lasers successfully argued patent infringement, leading to damages and injunctive relief.
  • Thermage challenged validity but failed to overturn the patents’ enforceability.
  • The dispute illustrates the strategic importance of patent protections in medical aesthetic devices.
  • The legal precedents from this case influence patent litigation strategies and intellectual property management in the industry.

FAQs

1. What was the central claim Alma Lasers made in this case?
Alma Lasers alleged Thermage infringed on its patents related to device technology for non-invasive skin tightening.

2. Did Thermage succeed in invalidating Alma’s patents?
No, the court upheld the patents' validity, rejecting Thermage’s invalidity defenses.

3. What remedies did Alma seek and receive?
Alma sought damages for patent infringement and a permanent injunction; it received both as part of the final judgment.

4. Has the case influenced industry patent strategies?
Yes, it underscores the need for robust patent portfolios and may encourage tighter patent prosecution and enforcement strategies.

5. Are there any ongoing legal issues related to this case?
No, the litigation was resolved in 2009; subsequent disputes involve other patents or companies.


References

  1. Court docket for Alma Lasers Ltd. v. Thermage Inc., U.S. District Court for the Northern District of California, case number 1:07-cv-00224.
  2. Patent documents: U.S. Patent Nos. 6,496,917 and 7,186,714.
  3. Court rulings and appellate opinions (published case summaries).
  4. Industry analyses of patent strategies in the aesthetic laser market.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.